Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658364 | 0.94 | HTR2A (0.58) | HTR1AHTR2ADRD2KMT2AMEN1 | |
| SCHEMBL5655859 | 0.93 | GFER (0.55) | HTR1AHTR2AKMT2AMEN1HTR2B | |
| SCHEMBL5656076 | 0.92 | HTR1A (0.53) | HTR1AHTR2ADRD2KMT2AMEN1 | |
| SCHEMBL5656794 | 0.91 | HTR1A (0.54) | HTR1ADRD2KMT2AMEN1POLB | |
| SCHEMBL5655788 | 0.91 | POLB (0.51) | HTR1ADRD2KMT2AMEN1POLB | |
| SCHEMBL5657925 | 0.90 | MAPT (0.54) | HTR1ADRD2POLBGFERMAPT | |
| SCHEMBL5658365 | 0.89 | HTR1A (0.56) | HTR1AHTR2ADRD2KMT2AMEN1 | |
| SCHEMBL5657553 | 0.89 | HTR1A (0.48) | HTR1AKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5657861 | 0.87 | OPRM1 (0.55) | HTR1AHTR2ADRD2SIGMAR1POLB | |
| SCHEMBL5656387 | 0.85 | HTR1A (0.61) | HTR1AHTR2ADRD2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HTR1A 8/4885HTR2A 14/4885DRD2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.